79.06 0.00 (0.00%)
After hours: 4:45PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||78.82 - 79.91|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2018|
|Forward Dividend & Yield||2.25 (2.82%)|
|1y Target Est||90.80|
Significant improvement in primary endpoint of progression-free survival previously reported; Improvement in objective response rate observed; Positive trend in overall survival did not reach statistical ...
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
INDIANAPOLIS, April 20, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology (AAN) annual meeting taking place April 21-27 in Los Angeles. Lilly will highlight a new analysis from three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab in patients who previously failed two or more preventive therapies as part of the "Best in Headache" platform session on Tuesday, April 24. Galcanezumab is a once-monthly, self-administered calcitonin gene-related peptide (CGRP) antibody currently under review by the U.S. Food and Drug Administration (FDA) for the prevention of migraine in adults.
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.
The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.